ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 22.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 351,339 shares of the biotechnology company’s stock after selling 99,936 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.15% of ADMA Biologics worth $7,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sei Investments Co. raised its position in shares of ADMA Biologics by 176.0% in the 1st quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock valued at $2,597,000 after purchasing an additional 250,925 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of ADMA Biologics by 9.2% in the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock worth $358,000 after buying an additional 4,570 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of ADMA Biologics by 114.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock worth $357,000 after buying an additional 28,832 shares during the period. Shell Asset Management Co. purchased a new stake in shares of ADMA Biologics during the first quarter valued at $155,000. Finally, EntryPoint Capital LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at $31,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $21.30 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a 50 day moving average price of $18.72 and a 200-day moving average price of $14.69. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 76.07 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ADMA. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This represents a 10.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 406,900 shares of company stock worth $7,128,521 over the last three months. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.